Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomised, Placebo-controlled, Double Blind, Parallel Group, Single Centre Study Investigating Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder

NCT06969937 is registered in ClinicalTrials.gov with Dr. med. Marcus Herdener as lead sponsor.

NCT NCT06969937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06969937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomised, Placebo-controlled, Double Blind, Parallel Group, Single Centre Study Investigating Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder
Lead sponsor
Dr. med. Marcus Herdener
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2025
Completion date
December 31, 2026
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol abuse/dependence, alcohol use disorder (aud), alcoholism